Lord, Abbett & Co
SWTX

Lord, Abbett & Co’s SpringWorks Therapeutics SWTX Stock Holding History

Lord, Abbett & Co’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-373,874
Closed -$16.5M – 580
2025
Q1 		$16.5M Sell
373,874
-571,934
-60% -$26.3M 0.06% 310
2024
Q4 		$34.2M Sell
945,808
-123,930
-12% -$4.33M 0.11% 231
2024
Q3 		$34.3M Sell
1,069,738
-1,004,232
-48% -$37.5M 0.11% 231
2024
Q2 		$78.1M Sell
2,073,970
-243,840
-11% -$10.3M 0.26% 108
2024
Q1 		$114M Buy
+2,317,810
New +$107M 0.37% 72
2022
Q2 		– Sell
-206,054
Closed -$11.6M – 623
2022
Q1 		$11.6M Sell
206,054
-172,953
-46% -$9.9M 0.03% 435
2021
Q4 		$23.5M Buy
379,007
+25,091
+7% +$1.66M 0.05% 375
2021
Q3 		$22.5M Buy
353,916
+308,468
+679% +$23.8M 0.05% 405
2021
Q2 		$3.75M Buy
+45,448
New +$3.45M 0.01% 616
2021
Q1 		– Sell
-42,032
Closed -$3.05M – 692
2020
Q4 		$3.05M Buy
+42,032
New +$2.71M 0.01% 613

Other funds holding SWTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Lord, Abbett & Co's SWTX Position: Q2 2025 in Review

Lord, Abbett & Co sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 373,874 shares — an estimated $16.5M sold.

Lord, Abbett & Co first reported a position in SWTX in Q4 2020 and held it in 10 quarters. The position peaked at $114M in Q1 2024. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Lord, Abbett & Co reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 373,874 SpringWorks Therapeutics shares in Q2 2025, an estimated $16.5M.
  • Lord, Abbett & Co first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 10 quarters.
  • Lord, Abbett & Co's SpringWorks Therapeutics position peaked at $114M in Q1 2024.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.